drugset / Trial / NCT00086983

Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors

NCT00086983

Phase 1 Terminated 15 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects and best dose of rebeccamycin analog and oxaliplatin in treating patients with refractory solid tumors. Drugs used in chemotherapy, such as rebeccamycin analog and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells

Timeline

Start
2004-05
Primary completion
2006-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule Intravenous
Subject becatecarin Other / unclassified Intravenous

Indications

No indication recorded.